RARE DISEASE
Staphylococcal necrotizing pneumonia
Staphylococcal necrotizing pneumonia
Staphylococcal necrotizing pneumonia
Drug discovery
1
drug
With orphan designation
Overview
Staphylococcal necrotizing pneumonia is a life-threatening pulmonary infection caused by Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus, typically methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains. It presents with abrupt-onset influenza-like symptoms (fever, cough), rapid progression to septic shock, leukopenia, hemoptysis, and multilobar necrosis on imaging. Mortality ranges from 40% to 60%, often within days of symptom onset [1][4][7].
Therapies
Empirical antibiotics: Immediate coverage for MRSA (e.g., vancomycin, linezolid) combined with β-lactams [2][3].
Toxin-targeting agents: Linezolid or clindamycin to suppress PVL production; adjunctive IV immunoglobulin (IVIG) in severe cases [8][12][16].
Supportive care: Early ICU admission for mechanical ventilation, pleural drainage, and hemodynamic stabilization [3][6].
Categories: rare infectious diseases, rare respiratory diseases
Research Papers
399 drug discovery papers about Staphylococcal necrotizing pneumonia, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
399 drug discovery papers about Staphylococcal necrotizing pneumonia, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-05-27 | Host Determinants of Toxicity and Inflammation: Learning from staphylococcal alpha-toxin
Staphylococcus aureus is a bacterium commonly found in humans. Approximately one-third of healthy adults carry this bacterium without becoming ill. However, S. aureus can cause infections with varying clinical manifestations. Most people develop only mild skin infections. In rare cases, life-threatening conditions such as necrotizing pneumonia or severe infections of the skin and soft tissues can occur. Why some people become seriously ill and others do not is not yet fully understood. An important factor in the disease caused by S. aureus is a toxin produced by the bacterium: α-toxin. This toxin creates small pores in the membrane of human cells, causing cells to be damaged or die. In this thesis, we investigated which variables contribute to how harmful this toxin is to human cells. We studied the molecular interaction between α-toxin and human cells and found that the toxin binds to an important and conserved component of the membrane protein ADAM10. In addition, we demonstrate that conditions within the body, such as the acidity (pH) of the environment, can strongly influence the activity of the toxin. Finally, we studied patients with a rare genetic defect in the OTULIN gene. These patients are, among other things, highly sensitive to the harmful effects of α-toxin and can consequently develop life-threatening infections. Our findings show that the severity of S. aureus infections is determined by both the bacterium and the host. The genetic makeup and environmental conditions within the body influence the sensitivity of human cells to substances produced by S. aureus. A better understanding of these interactions could contribute to more targeted treatments for severe bacterial infections in the future.
2026-03-02 | Necrotizing Pneumonia in an Elderly Patient With Chronic Obstructive Pulmonary Disease (COPD): A Case Report.
Necrotizing pneumonia (NP) is a severe complication of bacterial pneumonia, characterized by progressive lung necrosis and cavitation. Although advances in imaging and supportive care have improved outcomes, NP remains difficult to manage due to poor antibiotic penetration, frequent polymicrobial infection, and the lack of standardized treatment protocols. An 85-year-old man with chronic obstructive pulmonary disease (COPD) (Global Initiative for Obstructive Lung Disease (GOLD) group C) and a 40-pack-year former smoking history, managed with long-acting beta-agonist/long-acting muscarinic antagonist (LABA/LAMA), was admitted with acute dyspnea and productive cough. Imaging showed left-sided pneumonia, and methicillin-sensitive Staphylococcus aureus (MSSA) was isolated. Amoxicillin-clavulanate led to transient improvement, but recurrent fever, worsening hypoxemia, and new cavitary lesions developed. Antimicrobial therapy was broadened to piperacillin-tazobactam, vancomycin, and voriconazole, without clinical stabilization. After empiric meropenem, the patient improved, completed 21 days of treatment, and fully recovered. However, without microbiologic confirmation, a direct causal link to meropenem cannot be established. This case highlights the diagnostic and therapeutic challenges of necrotizing pneumonia in elderly COPD patients, particularly when differentiation between progression, relapse, or superinfection is hampered by inconclusive microbiological findings. Although clinical improvement followed escalation to meropenem, the evidence does not permit attribution of recovery solely to this intervention. These findings reinforce the need for frequent reassessment, individualized treatment strategies, and caution in generalizing therapeutic recommendations from individual case reports. Early identification of necrotizing complications and timely modification of antimicrobial therapy are critical. Broad-spectrum antibiotics, including carbapenems, should be reserved for cases with compelling clinical or microbiologic evidence of multidrug resistance, rather than being used routinely based on isolated case experiences.
2026-02-01 | Two-case cluster of rapidly progressive influenza B and Staphylococcus aureus pneumonia with one death.
To report a cluster of two epidemiologically linked construction workers with fulminant necrotizing pneumonia associated with co-infection by Panton-Valentine leukocidin (PVL)-positive methicillin-susceptible Staphylococcus aureus (MSSA) and influenza B virus. Clinical characteristics, imaging findings, and microbiological results were retrospectively reviewed. Metagenomic next-generation sequencing (mNGS) was performed on sputum and bronchoalveolar lavage fluid after conventional diagnostic tests failed to identify the causative pathogens. Following shared occupational exposure, both patients developed severe pneumonia. One patient experienced rapid progression and died. For the second patient, mNGS successfully identified co-infection with PVL-positive sequence type 22 MSSA and influenza B virus, prompting a timely shift to targeted antimicrobial therapy that led to survival after prolonged intensive care. This report demonstrates the extreme virulence of PVL-positive MSSA-influenza co-infection, highlights the diagnostic value of mNGS in severe treatment-refractory pneumonia, and emphasizes the need for effective respiratory protection in high-risk occupational environments.
2026-01-28 | Evaluation of lawsone as a potential inhibitor of Staphylococcus aureus efflux pump mediated drugs resistance: An in-vitro and in-silico study.
Staphylococcus aureus (S. aureus) is a causative agent of a wide range of infections such as staphylococcal scalded skin syndrome, toxic shock syndrome, necrotizing pneumonia, endocarditis, and osteomyelitis, posing a significant challenge in clinical management. This study explores the antibacterial potential of lawsone on S. aureus using experimental and computational methods. The minimum inhibitory concentration (MIC) of lawsone (alone and in combination with erythromycin, tetracycline, norfloxacin and ciprofloxacin) on 8 clinical multi-drug resistant S. aureus was evaluated in vitro. The ability of lawsone to modulate antibiotic susceptibility was also determined. Molecular docking was carried out to investigate the binding affinities between lawsone and five efflux pumps (EPP) (NorA, NorB, MsrA, SepA, and MefA) and a ribosomal protection protein (TetM) implicated in S. aureus drug resistance. Furthermore, molecular dynamics simulations (MDS) were performed to assess the stability of the protein-ligand complexes throughout the 100 ns simulation period. In addition, the physicochemical properties, drug-likeness, and toxicity of the lawsone were predicted. Lawsone showed synergistic effects with erythromycin, tetracycline, norfloxacin, and ciprofloxacin, as indicated by the modulation factors (MF) ranging from 2 to > 16. Notably, the strain SA383 showed MF values of > 8 for two antibiotics (ciprofloxacin and erythromycin), and > 16 for norfloxacin. Molecular docking revealed strong binding affinities between lawsone and the evaluated S. aureus drug resistant proteins. The MDS confirmed the stability of the lawsone-protein complexes over 100 ns simulation period, supporting its potential as an efflux pump inhibitor (EPI). ADMET profiling of lawsone demonstrated favorable drug-likeness, pharmacokinetics, and low toxicity. Lawsone does not inhibit major cytochrome P450 enzymes. Toxicity predictions also showed no significant risks of carcinogenicity or immunotoxicity, but potential mutagenicity and nephrotoxicity which require further study. Lawsone also exhibits no predicted activity on androgen receptors, aromatase, or GABA receptors, indicating minimal hormonal disruption. These findings highlight lawsone as a promising candidate for the development of a new EPI candidate, particularly against antibiotic-resistant S. aureus.
2026-01-22 | A case of necrotizing pneumonia leading to respiratory failure and tracheostomy.
Necrotizing pneumonia is a severe lung infection characterized by pulmonary necrosis and high mortality rates of up to 50 %. It is typically caused by toxin-producing pathogens, such as Staphylococcus aureus and Klebsiella pneumoniae. Limited guidelines exist for its management, making its treatment challenging. Case report: We discuss a case of a 58-year-old Malay woman with no significant comorbidity but developed necrotizing pneumonia. The diagnosis was confirmed using computed tomography (CT) of the thorax. Treatment with carbapenem, oxazolidinone and corticosteroid led to significant recovery. Conclusion: To date, no specific anti-inflammatory treatments exist for severe necrotizing pneumonia. Since systemic inflammation and multi-organ failure drive mortality, management focuses on supportive care aimed at maintaining oxygenation and hemodynamic stability to improve outcomes in critically ill patients.
2026-05-27 | Host Determinants of Toxicity and Inflammation: Learning from staphylococcal alpha-toxin
Staphylococcus aureus is a bacterium commonly found in humans. Approximately one-third of healthy adults carry this bacterium without becoming ill. However, S. aureus can cause infections with varying clinical manifestations. Most people develop only mild skin infections. In rare cases, life-threatening conditions such as necrotizing pneumonia or severe infections of the skin and soft tissues can occur. Why some people become seriously ill and others do not is not yet fully understood. An important factor in the disease caused by S. aureus is a toxin produced by the bacterium: α-toxin. This toxin creates small pores in the membrane of human cells, causing cells to be damaged or die. In this thesis, we investigated which variables contribute to how harmful this toxin is to human cells. We studied the molecular interaction between α-toxin and human cells and found that the toxin binds to an important and conserved component of the membrane protein ADAM10. In addition, we demonstrate that conditions within the body, such as the acidity (pH) of the environment, can strongly influence the activity of the toxin. Finally, we studied patients with a rare genetic defect in the OTULIN gene. These patients are, among other things, highly sensitive to the harmful effects of α-toxin and can consequently develop life-threatening infections. Our findings show that the severity of S. aureus infections is determined by both the bacterium and the host. The genetic makeup and environmental conditions within the body influence the sensitivity of human cells to substances produced by S. aureus. A better understanding of these interactions could contribute to more targeted treatments for severe bacterial infections in the future.
2026-03-02 | Necrotizing Pneumonia in an Elderly Patient With Chronic Obstructive Pulmonary Disease (COPD): A Case Report.
Necrotizing pneumonia (NP) is a severe complication of bacterial pneumonia, characterized by progressive lung necrosis and cavitation. Although advances in imaging and supportive care have improved outcomes, NP remains difficult to manage due to poor antibiotic penetration, frequent polymicrobial infection, and the lack of standardized treatment protocols. An 85-year-old man with chronic obstructive pulmonary disease (COPD) (Global Initiative for Obstructive Lung Disease (GOLD) group C) and a 40-pack-year former smoking history, managed with long-acting beta-agonist/long-acting muscarinic antagonist (LABA/LAMA), was admitted with acute dyspnea and productive cough. Imaging showed left-sided pneumonia, and methicillin-sensitive Staphylococcus aureus (MSSA) was isolated. Amoxicillin-clavulanate led to transient improvement, but recurrent fever, worsening hypoxemia, and new cavitary lesions developed. Antimicrobial therapy was broadened to piperacillin-tazobactam, vancomycin, and voriconazole, without clinical stabilization. After empiric meropenem, the patient improved, completed 21 days of treatment, and fully recovered. However, without microbiologic confirmation, a direct causal link to meropenem cannot be established. This case highlights the diagnostic and therapeutic challenges of necrotizing pneumonia in elderly COPD patients, particularly when differentiation between progression, relapse, or superinfection is hampered by inconclusive microbiological findings. Although clinical improvement followed escalation to meropenem, the evidence does not permit attribution of recovery solely to this intervention. These findings reinforce the need for frequent reassessment, individualized treatment strategies, and caution in generalizing therapeutic recommendations from individual case reports. Early identification of necrotizing complications and timely modification of antimicrobial therapy are critical. Broad-spectrum antibiotics, including carbapenems, should be reserved for cases with compelling clinical or microbiologic evidence of multidrug resistance, rather than being used routinely based on isolated case experiences.
2026-02-01 | Two-case cluster of rapidly progressive influenza B and Staphylococcus aureus pneumonia with one death.
To report a cluster of two epidemiologically linked construction workers with fulminant necrotizing pneumonia associated with co-infection by Panton-Valentine leukocidin (PVL)-positive methicillin-susceptible Staphylococcus aureus (MSSA) and influenza B virus. Clinical characteristics, imaging findings, and microbiological results were retrospectively reviewed. Metagenomic next-generation sequencing (mNGS) was performed on sputum and bronchoalveolar lavage fluid after conventional diagnostic tests failed to identify the causative pathogens. Following shared occupational exposure, both patients developed severe pneumonia. One patient experienced rapid progression and died. For the second patient, mNGS successfully identified co-infection with PVL-positive sequence type 22 MSSA and influenza B virus, prompting a timely shift to targeted antimicrobial therapy that led to survival after prolonged intensive care. This report demonstrates the extreme virulence of PVL-positive MSSA-influenza co-infection, highlights the diagnostic value of mNGS in severe treatment-refractory pneumonia, and emphasizes the need for effective respiratory protection in high-risk occupational environments.
2026-01-28 | Evaluation of lawsone as a potential inhibitor of Staphylococcus aureus efflux pump mediated drugs resistance: An in-vitro and in-silico study.
Staphylococcus aureus (S. aureus) is a causative agent of a wide range of infections such as staphylococcal scalded skin syndrome, toxic shock syndrome, necrotizing pneumonia, endocarditis, and osteomyelitis, posing a significant challenge in clinical management. This study explores the antibacterial potential of lawsone on S. aureus using experimental and computational methods. The minimum inhibitory concentration (MIC) of lawsone (alone and in combination with erythromycin, tetracycline, norfloxacin and ciprofloxacin) on 8 clinical multi-drug resistant S. aureus was evaluated in vitro. The ability of lawsone to modulate antibiotic susceptibility was also determined. Molecular docking was carried out to investigate the binding affinities between lawsone and five efflux pumps (EPP) (NorA, NorB, MsrA, SepA, and MefA) and a ribosomal protection protein (TetM) implicated in S. aureus drug resistance. Furthermore, molecular dynamics simulations (MDS) were performed to assess the stability of the protein-ligand complexes throughout the 100 ns simulation period. In addition, the physicochemical properties, drug-likeness, and toxicity of the lawsone were predicted. Lawsone showed synergistic effects with erythromycin, tetracycline, norfloxacin, and ciprofloxacin, as indicated by the modulation factors (MF) ranging from 2 to > 16. Notably, the strain SA383 showed MF values of > 8 for two antibiotics (ciprofloxacin and erythromycin), and > 16 for norfloxacin. Molecular docking revealed strong binding affinities between lawsone and the evaluated S. aureus drug resistant proteins. The MDS confirmed the stability of the lawsone-protein complexes over 100 ns simulation period, supporting its potential as an efflux pump inhibitor (EPI). ADMET profiling of lawsone demonstrated favorable drug-likeness, pharmacokinetics, and low toxicity. Lawsone does not inhibit major cytochrome P450 enzymes. Toxicity predictions also showed no significant risks of carcinogenicity or immunotoxicity, but potential mutagenicity and nephrotoxicity which require further study. Lawsone also exhibits no predicted activity on androgen receptors, aromatase, or GABA receptors, indicating minimal hormonal disruption. These findings highlight lawsone as a promising candidate for the development of a new EPI candidate, particularly against antibiotic-resistant S. aureus.
2026-01-22 | A case of necrotizing pneumonia leading to respiratory failure and tracheostomy.
Necrotizing pneumonia is a severe lung infection characterized by pulmonary necrosis and high mortality rates of up to 50 %. It is typically caused by toxin-producing pathogens, such as Staphylococcus aureus and Klebsiella pneumoniae. Limited guidelines exist for its management, making its treatment challenging. Case report: We discuss a case of a 58-year-old Malay woman with no significant comorbidity but developed necrotizing pneumonia. The diagnosis was confirmed using computed tomography (CT) of the thorax. Treatment with carbapenem, oxazolidinone and corticosteroid led to significant recovery. Conclusion: To date, no specific anti-inflammatory treatments exist for severe necrotizing pneumonia. Since systemic inflammation and multi-organ failure drive mortality, management focuses on supportive care aimed at maintaining oxygenation and hemodynamic stability to improve outcomes in critically ill patients.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Staphylococcal necrotizing pneumonia.
1 orphan drug designation for Staphylococcal necrotizing pneumonia.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin | antibodies | EMA | 2012-03-05 | — | Marcello Menapace |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.